Post-authorisation active surveillance of the Safety of COVID-19 Vaccine AstraZeneca (AZD-1222) in the UK: A consortium study - IRAS  292936

Patients who have received their first AstraZeneca COVID-19 vaccine are invited to participate in a study run by the Drug Safety Research Unit in Southampton which is monitoring the safety of this vaccine.

If you are interested and would like more information, please visit:-

or call

0800 619 6222

Patients are asked to register within 6 weeks of their first vaccination. 


Published: May 19, 2021